End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,755 KRW | +0.73% | +1.29% | -28.53% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.53% | 148M | - | ||
-17.86% | 8.35B | B+ | ||
+39.49% | 3.58B | C+ | ||
-38.71% | 2.46B | B- | ||
-8.06% | 2.47B | - | ||
-7.96% | 2.36B | B- | ||
-13.97% | 1.78B | C- | ||
-19.73% | 1.53B | A- | ||
-40.78% | 1.21B | C+ | ||
+8.32% | 1.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A084650 Stock
- Ratings LabGenomics Co., Ltd.